KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 141 filers reported holding KARYOPHARM THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $75,741 | -22.4% | 56,523 | +3.7% | 0.00% | -100.0% |
Q2 2023 | $97,580 | -33.2% | 54,514 | +45.1% | 0.00% | 0.0% |
Q1 2023 | $146,171 | +16.7% | 37,576 | +2.0% | 0.00% | 0.0% |
Q4 2022 | $125,215 | -36.4% | 36,828 | +1.8% | 0.00% | 0.0% |
Q3 2022 | $197,000 | +22.4% | 36,171 | +1.4% | 0.00% | 0.0% |
Q2 2022 | $161,000 | -38.8% | 35,660 | -0.2% | 0.00% | 0.0% |
Q1 2022 | $263,000 | +6.9% | 35,745 | -6.6% | 0.00% | 0.0% |
Q4 2021 | $246,000 | +7.4% | 38,262 | -2.9% | 0.00% | 0.0% |
Q3 2021 | $229,000 | -45.0% | 39,406 | -2.3% | 0.00% | 0.0% |
Q2 2021 | $416,000 | -4.4% | 40,342 | -2.4% | 0.00% | -50.0% |
Q1 2021 | $435,000 | -31.1% | 41,315 | +1.4% | 0.00% | 0.0% |
Q4 2020 | $631,000 | +3.1% | 40,760 | -2.8% | 0.00% | -33.3% |
Q3 2020 | $612,000 | -24.6% | 41,929 | -2.2% | 0.00% | -25.0% |
Q2 2020 | $812,000 | +19.8% | 42,883 | +21.6% | 0.00% | 0.0% |
Q1 2020 | $678,000 | -5.2% | 35,272 | -5.5% | 0.00% | +33.3% |
Q4 2019 | $715,000 | +100.3% | 37,310 | +0.6% | 0.00% | +200.0% |
Q3 2019 | $357,000 | +62.3% | 37,103 | +1.0% | 0.00% | 0.0% |
Q2 2019 | $220,000 | +20.2% | 36,723 | +17.2% | 0.00% | 0.0% |
Q1 2019 | $183,000 | -38.8% | 31,327 | -1.8% | 0.00% | 0.0% |
Q4 2018 | $299,000 | -45.4% | 31,916 | -0.8% | 0.00% | -50.0% |
Q3 2018 | $548,000 | +2.0% | 32,162 | +1.8% | 0.00% | 0.0% |
Q2 2018 | $537,000 | +76.1% | 31,582 | +39.0% | 0.00% | +100.0% |
Q1 2018 | $305,000 | +39.3% | 22,713 | -0.2% | 0.00% | 0.0% |
Q4 2017 | $219,000 | -12.0% | 22,766 | +0.5% | 0.00% | 0.0% |
Q3 2017 | $249,000 | +31.1% | 22,659 | +8.1% | 0.00% | 0.0% |
Q2 2017 | $190,000 | -10.0% | 20,965 | +27.7% | 0.00% | 0.0% |
Q1 2017 | $211,000 | +64.8% | 16,422 | +20.9% | 0.00% | – |
Q4 2016 | $128,000 | -99.9% | 13,586 | -0.3% | 0.00% | -100.0% |
Q3 2016 | $132,542,000 | +45.2% | 13,622 | +0.1% | 0.00% | – |
Q2 2016 | $91,269,000 | -27.0% | 13,602 | -3.0% | 0.00% | – |
Q1 2016 | $125,000,000 | -33.9% | 14,026 | -1.8% | 0.00% | -100.0% |
Q4 2015 | $189,000,000 | +127602.7% | 14,276 | +1.6% | 0.00% | 0.0% |
Q3 2015 | $148,000 | -100.0% | 14,050 | +0.1% | 0.00% | -50.0% |
Q2 2015 | $381,865,000 | +46.2% | 14,034 | +64.5% | 0.00% | +100.0% |
Q1 2015 | $261,134,000 | -18.2% | 8,531 | 0.0% | 0.00% | 0.0% |
Q4 2014 | $319,315,000 | +12.7% | 8,531 | +5.2% | 0.00% | 0.0% |
Q3 2014 | $283,398,000 | -24.8% | 8,111 | +0.1% | 0.00% | -50.0% |
Q2 2014 | $377,008,000 | +129.5% | 8,099 | +52.3% | 0.00% | +100.0% |
Q1 2014 | $164,273,000 | +38.1% | 5,318 | +2.5% | 0.00% | 0.0% |
Q4 2013 | $118,955,000 | – | 5,190 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Palo Alto Investors LP | 3,200,396 | $30,084,000 | 1.72% |
TFS CAPITAL LLC | 105,040 | $987,000 | 0.26% |
Tekla Capital Management LLC | 500,324 | $4,703,000 | 0.20% |
Piermont Capital Management Inc. | 51,080 | $480,000 | 0.11% |
ESSEX INVESTMENT MANAGEMENT CO LLC | 55,793 | $524,000 | 0.09% |
Candriam S.C.A. | 390,000 | $3,666,000 | 0.08% |
Virtus ETF Advisers LLC | 27,446 | $258,000 | 0.08% |
SECOR Capital Advisors, LP | 66,484 | $625,000 | 0.08% |
Trexquant Investment LP | 29,007 | $273,000 | 0.04% |
PRELUDE CAPITAL MANAGEMENT, LLC | 32,196 | $303,000 | 0.04% |